SCHEMBL6316902

SCHEMBL6316902

CCCCNC(=O)c1c(-c2ccccn2)noc1NC(=O)Cc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 5/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
GAA P10253 1/20 0.43
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CCNE1 P24864 1/20 0.41
CDK2 P24941 1/20 0.41
CDK5 Q00535 1/20 0.41
TSHR P16473 1/20 0.41
ASAH1 Q13510 1/20 0.40
HDAC1 Q13547 3/20 0.40
HDAC6 Q9UBN7 3/20 0.40
HDAC3 O15379 2/20 0.40
HDAC2 Q92769 2/20 0.40
HDAC4 P56524 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
NCOR2 Q9Y618 1/20 0.40
POLB P06746 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6322628 0.89 HTT (0.45) GAAHTTSMN1; SMN2TSHRHDAC1
SCHEMBL6318626 0.88 SMN1; SMN2 (0.47) L3MBTL1GAAHTTSMN1; SMN2TSHR
SCHEMBL6315466 0.88 NAAA (0.47) L3MBTL1GAAHTTSMN1; SMN2TSHR
SCHEMBL6323422 0.86 HTT (0.46) L3MBTL1GAAHTTSMN1; SMN2POLB
SCHEMBL6323312 0.85 HDAC3 (0.47) GAAHTTSMN1; SMN2TSHRHDAC3
SCHEMBL6315769 0.84 L3MBTL1 (0.42) L3MBTL1GAAHTTSMN1; SMN2TSHR
SCHEMBL6325190 0.83 HTT (0.46) L3MBTL1GAAHTTSMN1; SMN2TSHR
SCHEMBL6316894 0.83 MAPK14 (0.53) MAPK14CCNE1CDK2CDK5HDAC6
SCHEMBL6316498 0.82 GAA (0.43) L3MBTL1GAAHTTSMN1; SMN2TSHR
SCHEMBL6323976 0.82 NPC1 (0.46) MAPK14L3MBTL1GAASMN1; SMN2CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 MAPK14 111/4885L3MBTL1 4176/4885GAA 789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.